Management of Pseudomonas Infections

Indications for Double Antipseudomonal Coverage

The Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) recommend double antipseudomonal coverage for patients with high risk of mortality, prior intravenous antibiotic use within 90 days, structural lung disease, or in critically ill patients with suspected or confirmed Pseudomonas aeruginosa infections 1
Double coverage is indicated in patients requiring ventilatory support due to pneumonia, patients with septic shock, prior intravenous antibiotic use within 90 days, bronchiectasis, cystic fibrosis, or high-quality respiratory specimen with numerous and predominant gram-negative bacilli 1
In ICU settings with high risk of multidrug-resistant pathogens, double antipseudomonal coverage is recommended 2

Antibiotics should be selected from different classes with activity against P. aeruginosa, including β-lactam options (piperacillin-tazobactam, cefepime, ceftazidime, imipenem, meropenem, aztreonam) and second agent options (fluoroquinolones or aminoglycosides) 1
Aminoglycosides should never be used as the sole antipseudomonal agent 1

Once susceptibility results are available, de-escalation to appropriate monotherapy should be considered to reduce drug toxicity, risk of Clostridioides difficile infections, further antibiotic resistance, and treatment costs 1
For COVID-19 patients with secondary bacterial infections in ICU settings, double antipseudomonal coverage should follow local HAP/VAP guidelines, considering local epidemiology 2
For highly resistant strains, consider inhaled plus systemic antibiotics for VAP due to gram-negative bacilli susceptible only to aminoglycosides or polymyxins 1

Assess risk factors, including septic shock, ventilatory support, prior IV antibiotics, structural lung disease, and gram stain evidence of numerous gram-negative bacilli 1
If any risk factor is present, initiate double antipseudomonal coverage with agents from different classes, and select a β-lactam plus either a fluoroquinolone or aminoglycoside 1
If no risk factors are present, single antipseudomonal agent is appropriate, and de-escalate to targeted monotherapy if susceptibility allows 1